First Patient Dosed in Phase 2a Parkinson's Trial; Strategic Review Launched
JUNS is trading near its 52-week low of $2.33 (6.0% above the low).
Summary
Jupiter Neurosciences dosed the first patient in its Phase 2a RESET trial of JOTROL for Parkinson's disease, a key clinical milestone for its lead asset. The company also retained Tungsten Advisors to explore strategic options including sale, licensing, or partnerships. This follows a delisting determination from Nasdaq in August and a going concern warning in its latest 10-Q, making the strategic review a critical lifeline. The trial will enroll about 30 patients over 12 weeks, with data expected to inform future development. The announcement provides a positive clinical update amid severe financial distress, but the strategic process outcome remains uncertain.
At the time of this announcement, JUNS was trading at $2.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $2.33 to $135.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.